Palio – Never Be Forgotten header image 1

QRious about QR codes?

September 1st, 2010 · Creative, Industry Trends

From Chau Ho, Brand Designer, Palio

A QR reader app is required on your phone to read the code above: I suggest Barcode Reader for Android phones, Microsoft Tag for Windows phones, and NeoReader for iPhones and non-smartphones. All apps listed are free. If you don’t have a QR-reader equipped phone to view this post, you may read it by clicking on the QR code above.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:

“Does anybody have an idea?”

August 24th, 2010 · Creative

From Bob Rath, Associate Creative Director, Palio

“A new idea is delicate. It can be killed by a sneer or a yawn; it can be stabbed to death by a joke or worried to death by a frown on the right person’s brow.” – Charles Hendrickson Brower

Company President: “Does anybody have an idea?”

Employee: “Hey, I have an idea….”

Co-workers:

“Not that one again.”

“Here’s that same idea only different.”

“I have a build on that.”

“Love it… but here’s my idea.”

Managers:

“I think what you really mean is this.”

“I had that same idea five years ago.”

“Let’s all just worry about our own jobs. Okay?“

“Management is on that problem, so don’t worry about it!”

“Do yourself a big favor and don’t mention that again.”

Supervisors:

“That’s a disconnect”

“Nothins’ grabbin’ me.”

“Here, let me take a stab at it.”

“Are you trying to get yourself fired?!”

“I‘ll get back to you.”

Internal Group Meeting:

“We’ve always done it that way.”

“If it ain’t broke don’t fix it.”

“Let the other guys take the risk.”

“Let’s circle back on this.”

“That’s a great idea, for a Delicatessen!”

Group Director Meeting:

“I’m sorry…did you say something?”

“We’re not ready for that yet.“

“Well let’s run it up the flagpole, see who salutes it.”

“That’s interesting, BUT…

“Let’s put that on the back burner.”

Executive Manager Meeting:

“It sounds like change for the sake of change.”

“Isn’t someone else doing that?”

“If it’s still working okay, why change it?”

“It might have worked in your other place, but not here.”

“I vote leave well enough alone.”

Steering Committee:

“This business is different.“

“That could get us the wrong reputation.”

“Show me someone who’s done this successfully.”

“What’s so bad about things right now?“

“Great idea!… but not for us!“

Operating Committee

“Do you realize the paperwork it will cause!?”

“We’re all too busy.
”

“It’ll run up overhead.”

“That would be too difficult to administer.”

“Who’s gonna’ tell the big guy?”

Senior Executive V.P. Committee

“I think the fox is still loose!“

“How bout we make a compromise?”

“Let’s discuss that offline…“

“Not on my watch!”

“If I hear one more suggestion, my head will explode.”

Company President: “Doesn’t anybody have an idea?

Employee: “Sigh!”

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:·

The 20 Best Social Media Campaigns – Ever!

August 23rd, 2010 · Social Media

From Mike Myers, President, Palio

There isn’t a week that goes by in recent months that a client or media publication doesn’t reach out to us to discuss social media. It’s the new “thing,” and everyone wants to make sure that they aren’t missing an opportunity to use social media to effectively market and manage their brand.

Surprising to some, social media isn’t that “new.” It’s been used in various ways for years. Yes, social media on the Internet.

Forbes Magazine put out a great article last week reviewing their analysis of the Top 20 social media campaigns. We thought it was well done and very interesting. A quick review will show you how clients and brands have been creating buzz and engaging customers for well over 10 years using the “latest rage.”

We’ve taken the original Forbes list and commentary, placed it into PowerPoint for easy review, provided a set of worthwhile and interesting links, and embedded it here via a SlideShare plug-in for WordPress.

If you’d like to download it for yourself, here is the link.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:····

Going Visual

August 19th, 2010 · Creative

From Alan Steele, VP, Director of Studio Services, Palio

A review of: Going Visual - Using Images to Enhance Productivity, Decision Making and Profits, by Alexis Gerard and Bob Goldstein

This book, which is in Palio’s creative resources library, proposes that images are the best new tool to significantly improve business. Using the analogy of a Bach concert in 1500, the authors argue that, although we have a surviving music score, information about audience reaction, the look and feel of the concert space, the sound of the instruments, and the interaction between orchestra members is lost. The limitations of the written word as a descriptive tool are clear.

Humans, the authors point out, process the world visually. We have significantly more nerve fiber connections between our brain and optic nerve than between our brain and our other senses. However, we need a technology to capture and share images. There are three variables to image capture/sharing: skill level, time requirements, and audience reach. Through most of human history, up until still photography, skill level and time requirements were very high and audience reach was very low. Think of a highly skilled Renaissance oil painter and his courtly audience. With film photography, then digital photography and digital video, skill level and time requirements are low and audience reach is high. Think of you with a point-and-shoot digital camera and a quick download to your Facebook site.

The authors cite five case studies where images are incorporated into business process. A facilities management firm uses images to show where property needs repair. A self-employed sales rep takes photos of products from her 150 manufacturers and shares them with clients instead of lugging around the physical products. An SVP of merchandising for a chain of retail stores travels globally, photographing unique products. Designers also send her digital photos of concept renderings. An outdoor advertising company tags images with information making them “smart.” For example, the metadata attached to a billboard in Los Angeles includes a specific location, the advertiser, expiration date of the contract, etc. The company can “pre visualize” a property by superimposing a billboard on a proposed site. A project manager for an international entertainment company uses videoconferencing so globally dispersed team members can be together. There is less travel, tighter contact, and quicker business decisions.

There are five future directions for images in the business environment – 1) Imaging ecosystem: reducing the barriers to seamless image communication, ensuring that images flow freely across devices, software, and networks, 2) Visual mobility: the mobile phone is just the beginning, “real-time business” captures and communicates information instantly regardless of where the sender and receiver are located, 3) Automatic imaging: CCTV, web cams, reconnaissance satellites are examples of continuous, unattended, network-connected imaging devices, 4) Vivid imaging: a “long” picture of 1 to 10 seconds enables the viewer to feel part of an environment (a 360° view of a home is an example), and 5) Personalized authoring: video editing software that creates different videos for different audiences from the same content.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:···

Novelty or not, I’m into the iPad — hook, line, and sinker

August 16th, 2010 · Creative, Media

From Amanda Murphy, Senior Copywriter, Palio

Erin Rossi, Palio Art Director extraordinaire, and I recently attended a conference sponsored by The Big Money: Untethered 2010: Profitable Media in the Tablet Era, where some pretty prominent folks from companies like Condé Nast Digital, Sony, HealthCentral, Zagat Survey, Simon & Schuster, Google, Razorfish, and one of the guys responsible for a little campaign known as Apple “1984” sat on stage and spewed their feelings about the iPad and its potential effect on their business. Feelings that left it obvious as to who thinks the iPad is just another me-too device and who thinks it’s the sliced bread, peanut butter, AND jelly all rolled into one sparkling, shiny package.

All in all, the content was noteworthy. The speakers were impressive. The new Blio software for e-readers was snazzy. The mini cupcakes were mini.

But the most fascinating point to me was this quote from Shiv Singh, Vice President of Razorfish (forgive me if I butcher this, Shiv. I’m not a journalist): “The average time a user spent on the GQ iPad app was 62 minutes.” Wow. 62 minutes? And just the other day, I read on Adrants that ads on the iPad perform 6 times better than on a desktop. Double wow. In advertising, where you’re thrilled if a user spends more than a few seconds on your site, or you somehow achieve a 2% click-through rate from e-mail, this is big. Maybe the reason for these statistics is due to the novelty of the iPad, but methinks it’s much more.

Imagine an app created solely with your client’s brand and target in mind. Let’s take diabetes for example. With one app, patients could monitor blood sugar levels, keep track of their eating and exercise, set up reminders to take their medication, learn all about the product being promoted, etc. Sound just like a regular ol’ Web site? Re-read that GQ statistic, my friend, and think again.

Or, what if you could score for your client a single-sponsorship on an app relevant to their brand? Wait. Forget single-sponsorship, any amount of advertising you can land where users are spending an hour plus with their eyes and fingertips glued to the iPad just tapping and browsing and interacting is mind blowing.

This is incredibly exciting news for advertisers, because it means we get to experiment with the latest and greatest whiz bang device and expand our capabilities to gain new clients. (And ideally, it also means we get to play with the devices that create the whiz bang.) But, advertisers, this is equally exciting news for you. It means the chances for your ad to be not only read but acted upon, increase exponentially—by 6 times, to be exact-ish.

So, yeah, the iPad really is changing everything from turning flat content into a truly dynamic, user experience to showing us marketers how to take advantage of that content without crowding the marketplace.

Now that we’ve got the question of making media on a tablet more profitable all figured out, the only thing left to learn is just how this iAds works.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:····

Widgets Beware!

August 13th, 2010 · Medical Strategy, advertising

From Ian DeMeritt, Senior Medical Writer, Palio

In what may be the first DDMAC letter to focus on Facebook, Novartis Pharmaceuticals was just warned that its use of Share Widgets on the Tasigna (nilotinib) Web site was illegal and that it misbranded the drug. Tasigna is “indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive [Ph+] chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib.” The Tasigna PI contains a boxed warning and the FDA required a REMS program for Tasigna to educate healthcare providers and patients about proper dosing strategies to avoid serious risks.

The Tasigna Web site contained several Share Widgets. By clicking on these icons, visitors were able to quickly and easily share information about Tasigna on Facebook, Twitter, or other social media sites. A short description of Tasigna (including its indication) and a link to the Tasigna Web site would then appear on the user’s Facebook page visible for all of his or her friends to see. Although users were unable to edit the Novartis-generated text, they could include comments along with the post.

While I applaud this use of social media by Novartis, there was only one problem with this approach that anyone familiar with recent DDMAC communication in this area could predict (except, apparently, the Novartis regulatory team): no safety information was included on the Facebook pages of visitors who shared the link. Even though a link to the Tasigna Web site was present, DDMAC has made it pretty clear over the past couple of years that when it comes to social media, it doesn’t recognize a so-called “one-click rule.”

To my knowledge, this issue was first addressed by DDMAC in the 2008 untitled letter regarding banner advertisements for Diovan; this letter was also issued to none other than Novartis. That letter clearly stated the need to include safety information in on-line communications, and that a link to safety information is insufficient to communicate risk information:

“The [Diovan] banners, however, entirely omit all risk information, including the warnings, precautions, and the most frequently reported adverse events from the PI. We note that a link to the PI and Patient Product Information (PPI) is included at the bottom of the banners. However, this does not mitigate the misleading omission of risk information from the banners.”

Not surprisingly, DDMAC’s position hasn’t changed in the past 2 years. The following wording from the latest letter is nearly a direct copy-and-paste from the letter issued in 2008:

“We note that the shared content contains a hyperlink to various Tasigna product websites, which do contain risk information. However, the inclusion of such a hyperlink is insufficient to mitigate the misleading omission of risk information from these promotional materials.”

Given the previous communications between DDMAC and Novartis, I find it curious that they continue to test the “one-click rule.” Whether this latest misstep was intentional or not, it highlights the fact that the issue of pharmaceutical advertising in social media is not going away. Until DDMAC releases its guidance on social media these issues will continue to surface and DDMAC will continue to issue letters to companies who fail to comply.

Until then, I wonder if DDMAC will accept my friend request.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:·······

52 Cool Facts About Social Media

August 12th, 2010 · Social Media

From Mike Myers, President, Palio

We’re big fans of Michael Gass’ ‘Fueling Ad Agency New Business’ blog. He regularly posts interesting insights that are worthy of a read regardless of your position or industry.

Michael recently wrote a blog post entitled “52 Facts About Social Media for Ad Agency New Business” that drew from a blog post by Danny Brown.

This summary is directly drawn from the content that these two published. We found it interesting, timely, and worthy of passing along.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ No CommentsTags:·····

The Power of Design

August 11th, 2010 · Creative

From Rafael Holguin, SVP, Director of Design, Palio

It would be unfair of me to write about the design of medicine labels and brand identity in pharmaceutical products without looking back. After researching, I was amazed by the artistic quality and fascinating shaped bottles, typographic labels, interesting ingredients and elegant color palettes. In those days elixirs, liniments, syrups, pills, extracts, tonics and balms were produced and distributed by doctors themselves!

Until around 150 years ago, anyone could call themselves a chemist or druggist. The first steps in regulating the profession came in 1842 with the founding of the Pharmaceutical Society.

Some of the substances prohibited today were legally available in the past. Interestingly, the world-famous soft drink, Coca-Cola, was initially made from a syrup that listed as an ingredient, coca. John Pemberton (1831-1888), a pharmacist from Atlanta, Georgia sold many tonics and elixirs, and among them was Coke syrup known to have a medicinal or sedating effect. At that time, the addictive and harmful qualities of cocaine were not known and it wasn’t illegal in the U.S. It isn’t surprising that we won’t find this historical fact in the Coca-Cola website. It’s fascinating to me that one of the largest consumer brands in the world has such a direct link to the pharmaceutical industry.

Looking at the early 1800’s medicine vintage labels you would appreciate the exquisite handwritten and typographic treatments, printing techniques, and shapes and paper stock of the labels — some of them very simple and straightforward, others more ornate combinations of serif and sans serif typographies.

Very early on, physicians and marketers realized the importance of design in providing differentiation. Soon, greater competition began fueling more creativity. Nothing has changed in principle since then except that there are more regulations and controls designed to protect the public. For instance, when designing the brand identity of a pharmaceutical brand today, the generic name must appear below the product name at 50% of the height in size of the tallest character in the brand logotype, and legibility is extremely important.

It’s the same when choosing the color palette and symbols for a brand — the FDA regulates all aspects of advertising graphics to avoid confusion among products. This is very important to prevent the misuse of medicine by physicians, pharmacists, nurses and patients. It’s mandatory now that all pharmaceutical communication for both professionals and consumers is reviewed and approved by the FDA. This process is very strict. In addition, none of the visual and verbal branding elements can convey information that makes claims not supported by data.

Therefore, there is some creative limitation that could begin to genericize the marketing expression of a brand if we don’t seek to use the most artistic originality possible within our constraints. Adding to the difficulty are the rushed deadlines and then the focus-group factor that can hinder the good old-fashioned craftsmanship that produces truly great work.

Design innovation is imperative to produce breakthrough branding within these established boundaries. We can only do this if we carve out the proper amount of time to educate ourselves about the product profile, MOA, market dynamics and unmet needs of the audience and we don’t truncate the creative process. Obviously, it’s a lot easier to default to the typical expressions of the triumphant “jumping for joy” figure, the meaningless “swoosh,” or something so abstract or generic that it becomes completeley meaningless and non-differentiating.

However, there are some pharmaceutical brands that have achieved high design standards — like Nexium (the purple pill). Astra Zeneca’s Nexium managed to own the color purple in the mind of the world; purple is a “cool” color very appropriate for a medication prescribed to treat the symptoms of acid reflux and heartburn. Creating “the purple pill” was brilliant. Advair has followed this example with “the purple disk” and Pfizer’s Viagra did the same with “the blue pill.”

Of course, there are other famous pharma branding cases; Bayer aspirin is surely one. In 1897, chemist Felix Hoffmann, at Bayer in Germany, chemically synthesized a stable form of ASA powder that relieved his father’s rheumatism. The compound later became the active ingredient in aspirin, which took its name from the “a” in acetyl, the “spir” from the spirea plant (which yields salicin), and the addition of “in,” a common suffix for medications. In 1899, Bayer distributed aspirin powder to physicians to give to their patients, and it soon became the number one drug worldwide.

In branding, the biggest sign of success is when your product becomes synonymous with the category. People worldwide always refer to aspirin when speaking of medicine for headaches. Non pharmaceutical examples are Scotch tape, Xerox, FedEx and Google. I‘m convinced that great strategy and well designed brand names, colors, logotypes, symbols and concepts go a long way to ensure a brand’s memorability and acceptance… perhaps as much as fundamental factors like quality and efficacy.

Palio is a full-spectrum global pharmaceutical and consumer advertising, marketing, and communications agency that excels in brand creation and specializes in brand strategy, product launches, global marketing, and digital and integrated media.
Share
  • Share/Bookmark

→ 1 CommentTags:·····